Description / anti-human VEGFR-2/KDR, Antagonistic monoclonal antibody
VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. Human VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis. The antibody will bind near the ligand binding site of the receptor and has antagonistic activity by blocking the binding of natural ligands.
More Information
| Size | 100 µg |
|---|---|
| Source | Mouse |
| Isotype | IgG1 |
| Clone Nr. | (#6B11) |
| Species Reactivity | Human |
| Formulation | lyophilized |
| Buffer | PBS |
| Reconstitution | Centrifuge the vial prior to opening. Reconstitute the antibody with 200 µl sterile PBS and the final concentration is 500 µg/ml. |
| Stability and Storage | Lyophilized samples are stable for 2 years from date of receipt when stored at -20°C. Reconstituted antibody can be aliquoted and stored frozen at < -20°C for at least six months without detectable loss of activity. |
| Preparation | This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a mouse immunized with purified human VEGFR2 N-terminal fragment (AA N30-200)). |
| Antigen | hVEGFR2 N-terminal fragment (N30-200) |
| Application | WB, Attenuation of VEGF-induced KDR tyrosine phosphorylation |
| Synonyms | vascular endothelial growth factor receptor-2 ; KDR; FLK1; CD309; VEGF receptor 2; kinase insert domain protein receptor |
| Uniprot ID | P35968 |
| Protein RefSeq | NP_002244.1 |
| mRNA RefSeq | NM_002253.2 |